Purchasing agent for Pazopanib in India Pazopanib price in India

WeChat consultation hotline If the call cannot be reached, please add WeChat or [other name] [Indications] Pazopanib is a tyrosine kinase inhibitor suitable for the treatment of patients with advanced renal cell carcinoma. [ ] [Dosage and administration] Take this medication orally once daily without food. Baseline moderate hepatic impairment – Take orally once daily. Not recommended for patients with severe liver damage. [Dosage form and strength] Tablets. [Mechanism of action] Pazopanib is a vascular endothelial growth factor receptor, a platelet-derived growth factor receptor, a fibroblast growth factor receptor, and a cytokine receptor. The interleukin receptor induces cellular kinases, leukocyte-specific protein tyrosine kinase, and A polytyrosine kinase inhibitor of transmembrane glycoprotein receptor tyrosine kinase. Pazopanib inhibits ligand-induced autophosphorylation of receptors in vitro In vivo pazopanib inhibits phosphorylation induced in mouse lungs in a mouse model of angiogenesis and some human tumors in mice Growth of transplanted tumors. [Pharmacodynamics and Pharmacokinetics] Increases in blood pressure have been observed and are related to plasma pazopanib steady-state trough concentrations. The prolongation potential of pazopanib was assessed as part of the loss of control. An open-label dose-escalation study in patients with advanced cancer. Patients received pazopanib at doses ranging from 0 to 100 mg/day. The effect of pazopanib on intervals was evaluated prior to serial collection on day 1 and single dose collection on days 1 and 2 . pts had and pts had an increase from baseline > . [See Warnings and Precautions] Absorption Pazopanib is absorbed orally and the median time to reach peak concentration is to hours after dosing. Daily dosing results in geometric means and are / and / respectively. There may be no consistent increase when pazopanib doses are exceeded. Administration of a single dose of pazopanib as a mashed tablet takes approximately twice as long and approximately twice as many hours as administration of the whole tablet. These results indicate an increase in the bioavailability and rate of oral absorption of pazopanib following administration of mashed tablets relative to administration of whole tablets. Therefore tablets should not be crushed due to this potential for increased exposure. The systemic exposure of pazopanib is increased when administered with food. Pazopanib administered with a high-fat or low-fat meal resulted in an approximately 2-fold increase. Pazopanib should therefore be administered at least one hour before or one hour after a meal [see Dosage and Administration. Distribution Pazopanib binds to human plasma proteins in vivo in a range to/without concentration dependence. In vitro studies suggest that pazopanib is a substrate of glycoproteins and breast cancer resistance proteins. Metabolism In vitro studies confirmed that pazopanib is metabolized with and to a minor extent. Elimination The mean half-life of pazopanib is hours after administration of the recommended dose. Elimination through the feces and renal elimination account for the administered dose. [Warnings and Precautions] Editor) Increased serum aminotransferase levels and bilirubin were observed. Severe fatal hepatotoxicity has occurred. Measure liver chemistries before starting treatment and periodically during treatment. ) Septal prolongation and torsades de pointes have been observed. Use with caution in patients at higher risk with prolonged interval between occurrences. Monitoring of ECG and electrolytes should be considered. ) Fatal bleeding events have been reported. It has not been studied in patients with a history of hemoptysis or clinically significant gastrointestinal bleeding within the past months and should not be used in these patients. ) Arterial thrombotic events and possible fatality have been observed. Use with caution in patients at increased risk for these events. ) Gastrointestinal perforation or fistula has occurred. Fatal perforations have occurred. Use with caution in patients with increased risk of gastrointestinal perforation or fistula. ) Hypertension has been observed. Blood pressure should be adequately controlled when started. Monitor and treat hypertension as needed. ) Treatment interruption is recommended in patients undergoing surgery. ) Hypothyroidism may occur. It is recommended to monitor thyroid function. ) Proteinuria Monitor urine protein. Interrupt medications for grade proteinuria. ) may harm the fetus when given to a pregnant woman. Women of pregnancy potential should be advised of the potential harm to the fetus and should avoid pregnancy. )